SEARCH

SEARCH BY CITATION

References

  • 1
    Liouville H. Retrecissement cardiaque sous aortique. Gaz Med (Paris) 1869;24:1615.
  • 2
    Schmincke A. Ueber linkseitige muskulose conusstenosen. Dtsch Med Wochenschr 1907;33:2082.
  • 3
    Braunwald E, Ebert PA. Hemogynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs. Am J Cardiol 1962;10:48995.
  • 4
    Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr, Morrow AG. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. Circulation 1964;30(Suppl. 4):3119. Suppl-119.
  • 5
    Morrow AG, Lambrew CT, Braunwald E. Idiopathic hypertrophic subaortic stenosis. II. Operative treatment and the results of pre- and postoperative hemodynamic evaluations. Circulation 1964;30(Suppl. 4):12051. Suppl-51.
  • 6
    Henry WL, Clark CE, Epstein SE. Asymmetric septal hypertrophy. Echocardiographic identification of the pathognomonic anatomic abnormality of IHSS. Circulation 1973;47:22533.
  • 7
    Boughner DR, Schuld RL, Persaud JA. Hypertrophic obstructive cardiomyopathy. Assessment by echocardiographic and Doppler ultrasound techniques. Br Heart J 1975;37:91723.
  • 8
    Joyner CR, Harrison FS Jr, Gruber JW. Diagnosis of hypertrophic subaortic stenosis with a Doppler velocity flow detector. Ann Intern Med 1971;74:6926.
  • 9
    Maron BJ, Gottdiener JS, Arce J, Rosing DR, Wesley YE, Epstein SE. Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler echocardiography. J Am Coll Cardiol 1985;6:118.
  • 10
    Takenaka K, Dabestani A, Gardin JM, Russell D, Clark S, Allfie A et al. Left ventricular filling in hypertrophic cardiomyopathy: a pulsed Doppler echocardiographic study. J Am Coll Cardiol 1986;7:126371.
  • 11
    Nagueh SF, McFalls J, Meyer D, Hill R, Zoghbi WA, Tam JW et al. Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 2003;108:3958.
  • 12
    Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 2001;104:12830.
  • 13
    Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990;62:9991006.
  • 14
    Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:40512.
  • 15
    Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:36573.
  • 16
    Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:2114.
  • 17
    Seggewiss H. Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy. Curr Cardiol Rep 2001;3:1606.
  • 18
    Talreja DR, Nishimura RA, Edwards WD, Valeti US, Ommen SR, Tajik AJ et al. Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol 2004;44:232932.
  • 19
    Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008;118:1319.
  • 20
    Lombardi R, Rodriguez G, Chen SN, Ripplinger CM, Li W, Chen J et al. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 2009;119:1398407.
  • 21
    Marian AJ, Senthil V, Chen SN, Lombardi R. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol 2006;47:82734.
  • 22
    Senthil V, Chen SN, Tsybouleva N, Halder T, Nagueh SF, Willerson JT et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res 2005;97:28592.
  • 23
    Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:31724.
  • 24
    Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001;103:78991.
  • 25
    Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92:7859.
  • 26
    Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998;338:124857.
  • 27
    Niimura H, Patton KK, McKenna WJ, Soults J, Maron BJ, Seidman JG et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 2002;105:44651.
  • 28
    Nienaber CA, Hiller S, Spielmann RP, Geiger M, Kuck KH. Syncope in hypertrophic cardiomyopathy: multivariate analysis of prognostic determinants. J Am Coll Cardiol 1990;15:94855.
  • 29
    Kofflard MJM, Ten Cate FJ, Van Der Lee C, Van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003;41:98793.
  • 30
    Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990;15:127985.
  • 31
    Kofflard MJ, Waldstein DJ, Vos J, Ten Cate FJ. Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am.J Cardiol 1993;72:93943.
  • 32
    Cannan CR, Reeder GS, Bailey KR, Melton LJ III, Gersh BJ. Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Circulation 1995;92:248895.
  • 33
    Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009;119:108592.
  • 34
    Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996;276:199204.
  • 35
    Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:177885.
  • 36
    Elliott PM, Gimeno B Jr, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001;357:4204.
  • 37
    Marian AJ. On predictors of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol 2003;41:9946.
  • 38
    Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42:8739.
  • 39
    Frenneaux MP. Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart 2004;90:5705.
  • 40
    Maron BJ, Niimura H, Casey SA, Soper MK, Wright GB, Seidman JG et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol 2001;38:31521.
  • 41
    Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992;326:110814.
  • 42
    Watkins H, Conner D, Thierfelder L, Jarcho JA, MacRae C, McKenna WJ et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995;11:4347.
  • 43
    Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994;77:70112.
  • 44
    Olson TM, Doan TP, Kishimoto NY, Whitby FG, Ackerman MJ, Fananapazir L. Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol 2000;32:168794.
  • 45
    Mogensen J, Murphy RT, Kubo T, Bahl A, Moon JC, Klausen IC et al. Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:231525.
  • 46
    Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O’Donoghue A et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995;332:105864.
  • 47
    Knoll R, Hoshijima M, Hoffman HM, Person V, Lorenzen-Schmidt I, Bang ML et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 2002;111:94355.
  • 48
    Osio A, Tan L, Chen SN, Lombardi R, Nagueh SF, Shete S et al. Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res 2007;100:7668.
  • 49
    Daw EW, Lu Y, Marian AJ, Shete S. Identifying modifier loci in existing genome scan data. Ann Hum Genet 2008;72:6705.
  • 50
    Daw EW, Chen SN, Czernuszewicz G, Lombardi R, Lu Y, Ma J et al. Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. Hum Mol Genet 2007;16:246371.
  • 51
    Marian AJ. Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol 2002;17:24252.
  • 52
    Patel R, Lim DS, Reddy D, Nagueh SF, Lutucuta S, Sole MJ et al. Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol 2000;32:236977.
  • 53
    Brugada R, Kelsey W, Lechin M, Zhao G, Yu QT, Zoghbi W et al. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. J Investig Med 1997;45:54251.
  • 54
    Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005;352:36272.
  • 55
    Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA et al. Prevalence of fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004;110:104753.
  • 56
    Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L et al. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 2001;104:30303.
  • 57
    Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Hassan AS et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001;344:182331.
  • 58
    Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001;10:121520.
  • 59
    Tardiff JC, Hewett TE, Palmer BM, Olsson C, Factor SM, Moore RL et al. Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest 1999;104:46981.
  • 60
    Morimoto S, Lu QW, Harada K, Takahashi-Yanaga F, Minakami R, Ohta M et al. Ca(2+)-desensitizing effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy. Proc Natl Acad Sci USA 2002;99:9138.
  • 61
    Harada K, Potter JD. Familial hypertrophic cardiomyopathy mutations from different functional regions of troponin T result in different effects on the pH and Ca2+ sensitivity of cardiac muscle contraction. J Biol Chem 2004;279:1448895.
  • 62
    Nagueh SF, Chen S, Patel R, Tsybouleva N, Lutucuta S, Kopelen HA et al. Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy. J Mol Cell Cardiol 2004;36:66373.
  • 63
    Sarikas A, Carrier L, Schenke C, Doll D, Flavigny J, Lindenberg KS et al. Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc Res 2005;66:3344.
  • 64
    Sirenko SG, Potter JD, Knollmann BC. Differential effect of troponin T mutations on the inotropic responsiveness of mouse hearts – role of myofilament Ca2+ sensitivity increase. J Physiol Online 2006;575:20113.
  • 65
    Sata M, Ikebe M. Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome. J Clin Invest 1996;98:286673.
  • 66
    Fujita H, Sugiura S, Momomura S, Omata M, Sugi H, Sutoh K. Characterization of mutant myosins of Dictyostelium discoideum equivalent to human familial hypertrophic cardiomyopathy mutants. Molecular force level of mutant myosins may have a prognostic implication. J Clin Invest 1997;99:10105.
  • 67
    Sweeney HL, Feng HS, Yang Z, Watkins H. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Proc Natl Acad Sci USA 1998;95:1440610.
  • 68
    Tardiff JC, Factor SM, Tompkins BD, Hewett TE, Palmer BM, Moore RL et al. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin Invest 1998;101:280011.
  • 69
    Georgakopoulos D, Christe ME, Giewat M, Seidman CM, Seidman JG, Kass DA. The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation [see comments]. Nat Med 1999;5:32730.
  • 70
    Morimoto S, Nakaura H, Yanaga F, Ohtsuki I. Functional consequences of a carboxyl terminal missense mutation Arg278Cys in human cardiac troponin T. Biochem Biophys Res Commun 1999;261:7982.
  • 71
    Nakaura H, Morimoto S, Yanaga F, Nakata M, Nishi H, Imaizumi T et al. Functional changes in troponin T by a splice donor site mutation that causes hypertrophic cardiomyopathy. Am J Physiol 1999;277:C22532.
  • 72
    Nakaura H, Yanaga F, Ohtsuki I, Morimoto S. Effects of missense mutations Phe110Ile and Glu244Asp in human cardiac troponin T on force generation in skinned cardiac muscle fibers. J Biochem (Tokyo) 1999;126:45760.
  • 73
    Swynghedauw B. Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles. Physiol Rev 1986;66:71071.
  • 74
    Marian AJ, Wu Y, Lim DS, McCluggage M, Youker K, Yu QT et al. A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest 1999;104:168392.
  • 75
    Lombardi R, Bell A, Senthil V, Sidhu J, Noseda M, Roberts R et al. Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovasc Res 2008;79:10917.
  • 76
    Solaro RJ, Varghese J, Marian AJ, Chandra M. Molecular mechanisms of cardiac myofilament activation: modulation by pH and a troponin T mutant R92Q. Basic Res Cardiol 2002;97(Suppl. 1):I10210.
  • 77
    Harada K, Takahashi-Yanaga F, Minakami R, Morimoto S, Ohtsuki I. Functional consequences of the deletion mutation deltaGlu160 in human cardiac troponin T. J Biochem 2000;127:2638.
  • 78
    Montgomery DE, Tardiff JC, Chandra M. Cardiac troponin T mutations: correlation between the type of mutation and the nature of myofilament dysfunction in transgenic mice. J Physiol 2001;536:58392.
  • 79
    Szczesna D, Zhang R, Zhao J, Jones M, Guzman G, Potter JD. Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. J Biol Chem 2000;275:62430.
  • 80
    Yanaga F, Morimoto S, Ohtsuki I. Ca2+ sensitization and potentiation of the maximum level of myofibrillar ATPase activity caused by mutations of troponin T found in familial hypertrophic cardiomyopathy. J Biol Chem 1999;274:880612.
  • 81
    Hernandez OM, Szczesna-Cordary D, Knollmann BC, Miller T, Bell M, Zhao J et al. F110I and R278C troponin T mutations that cause familial hypertrophic cardiomyopathy affect muscle contraction in transgenic mice and reconstituted human cardiac fibers. J Biol Chem 2005;280:3718394.
  • 82
    Haim TE, Dowell C, Diamanti T, Scheuer J, Tardiff JC. Independent FHC-related cardiac troponin T mutations exhibit specific alterations in myocellular contractility and calcium kinetics. J Mol Cell Cardiol 2007;42:1098110.
  • 83
    Rust EM, Albayya FP, Metzger JM. Identification of a contractile deficit in adult cardiac myocytes expressing hypertrophic cardiomyopathy-associated mutant troponin T proteins. J Clin Invest 1999;103:145967.
  • 84
    Tobacman LS, Lin D, Butters C, Landis C, Back N, Pavlov D et al. Functional consequences of troponin T mutations found in hypertrophic cardiomyopathy. J Biol Chem 1999;274:2836370.
  • 85
    Gautel M. The sarcomere and the nucleus: functional links to hypertrophy, atrophy and sarcopenia. Adv Exp Med Biol 2008;642:17691.
  • 86
    Hoshijima M. Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures. Am J Physiol Heart Circ Physiol 2006;290:H131325.
  • 87
    Hayashi T, Arimura T, Itoh-Satoh M, Ueda K, Hohda S, Inagaki N et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol 2004;44:2192201.
  • 88
    Marian AJ. Experimental therapies in hypertrophic cardiomyopathy. J Cardiovasc Transl Res 2009;2:48392.
  • 89
    Marian AJ. Contemporary treatment of hypertrophic cardiomyopathy. Tex Heart Inst J 2009;36:194204.
  • 90
    Maron BJ, Nichols PF III, Pickle LW, Wesley YE, Mulvihill JJ. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am J Cardiol 1984;53:108794.
  • 91
    Greaves SC, Roche AH, Neutze JM, Whitlock RM, Veale AM. Inheritance of hypertrophic cardiomyopathy: a cross sectional and M mode echocardiographic study of 50 families. Br Heart J 1987;58:25966.
  • 92
    Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002;105:29927.
  • 93
    Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, Kermani BG et al. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 2010;327:7881.
  • 94
    Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:12518.
  • 95
    Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004;109:128491.
  • 96
    Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 2006;103:462833.
  • 97
    Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007;49:2418.